文献速递淋巴瘤

纳武利尤单抗-AVD 对比维布妥昔单抗-AVD 治疗入组 S1826 研究的老年晚期经典型霍奇金淋巴瘤患者

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
PubMed 文献 · J Clin Oncol · 2025-06-16

本文报告 S1826 三期试验中 60 岁及以上老年患者的亚组分析,99 例初诊晚期经典型霍奇金淋巴瘤患者随机接受纳武利尤单抗-AVD 或维布妥昔单抗-AVD 六周期治疗。中位随访 2.1 年,纳武利尤单抗-AVD 的 2 年无进展生存率为 89%,维布妥昔单抗-AVD 为 64%,前者耐受性更好且更有效,成为适合蒽环类联合治疗的老年晚期经典型霍奇金淋巴瘤患者的新标准治疗。

要点

  • 纳武利尤单抗-AVD 组 2 年无进展生存率 89%,维布妥昔单抗-AVD 组 64%(HR 0.24)。
  • 纳武利尤单抗-AVD 组 2 年总生存率 96%,维布妥昔单抗-AVD 组 85%(HR 0.16)。
  • 维布妥昔单抗-AVD 组非复发死亡率 16%,纳武利尤单抗-AVD 组 6%。

核心结论

  • 纳武利尤单抗-AVD 较维布妥昔单抗-AVD 耐受性更好且更有效,因此成为适合蒽环类联合治疗的老年晚期经典型霍奇金淋巴瘤患者的新标准治疗。

研究设计与样本

  • SWOG 开展的 S1826 三期试验的老年患者亚组分析,纳入 60 岁及以上初诊晚期(III-IV 期)经典型霍奇金淋巴瘤患者,随机接受六周期纳武利尤单抗-AVD 或维布妥昔单抗-AVD 治疗。
  • 入组 60 岁及以上患者 103 例,其中 99 例符合条件。

主要发现

  • 中位随访 2.1 年,纳武利尤单抗-AVD 组(n=50)2 年无进展生存率 89%,维布妥昔单抗-AVD 组(n=49)64%(HR 0.24,95%CI 0.09-0.63,单侧分层 log-rank P=0.001)。
  • 纳武利尤单抗-AVD 组 2 年总生存率 96%,维布妥昔单抗-AVD 组 85%(HR 0.16,95%CI 0.03-0.75,分层单侧 log-rank P=0.005)。
  • 六周期治疗未减量完成者纳武利尤单抗-AVD 组 69%,维布妥昔单抗-AVD 组 26%;维布妥昔单抗-AVD 组 55% 中止维布妥昔单抗,纳武利尤单抗-AVD 组 14% 中止纳武利尤单抗。
  • 非复发死亡率维布妥昔单抗-AVD 组 16%,纳武利尤单抗-AVD 组 6%;尽管纳武利尤单抗-AVD 组中性粒细胞减少更多,但维布妥昔单抗-AVD 组发热性中性粒细胞减少、脓毒症和感染以及周围神经病变更高。
  • 患者报告的关键不良事件结局证实纳武利尤单抗-AVD 较维布妥昔单抗-AVD 毒性特征更优。

临床怎么用

  • 纳武利尤单抗-AVD 是适合蒽环类联合治疗的老年晚期经典型霍奇金淋巴瘤患者的新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three S1826 trial conducted by SWOG that randomly assigned patients with newly diagnosed advanced-stage (III-IV) cHL to six cycles of nivolumab (N)-AVD or brentuximab vedotin (BV)-AVD. Of 103 enrolled patients 60 years and older, 99 were eligible. At a median follow-up of 2.1 years, the 2-year progression-free survival was 89% after N-AVD (n = 50) and 64% after BV-AVD (n = 49, HR 0.24, 95%CI 0.09-0.63, 1-sided stratified log-rank P = .001). The 2-year OS was 96% with N-AVD versus 85% with BV-AVD (HR 0.16, 95%CI 0.03-0.75 stratified 1-sided log-rank P = .005). Six cycles were delivered without dose reduction in 69% on N-AVD and 26% on BV-AVD; 55% discontinued BV, and 14% discontinued nivolumab. The nonrelapse mortality was 16% with BV-AVD and 6% with N-AVD. Despite more neutropenia with N-AVD, febrile neutropenia, sepsis, and infections were higher with BV-AVD, as was peripheral neuropathy. Patient-reported outcomes of key adverse events confirmed the improved toxicity profile of N-AVD over BV-AVD. N-AVD was better tolerated and more effective than BV-AVD and is therefore a new standard of care for older patients with advanced-stage cHL fit for anthracycline-based combination therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rutherford SC, Li H, Herrera AF, et al. Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. J Clin Oncol. 2025. PMID: 40523203. doi:10.1200/JCO-25-00204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。